KRAS, a New Target for Precision Medicine in Colorectal Cancer?

Fiche publication

Date publication

octobre 2024

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LAMBERT Aurélien

Tous les auteurs :
Boilève A, Smolenschi C, Lambert A, Boige V, Delaye M, Camilleri GM, Tarabay A, Valéry M, Fuerea A, Pudlarz T, Mathieu JRR, Jaulin F, Hollebecque A, Ducreux M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39456549

Résumé

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, with significant public health concerns. This review examines the landscape of KRAS inhibition in colorectal cancer (CRC), focusing on recent advances in therapeutic strategies targeting this oncogene. Historically deemed undruggable due to its complex structure and essential role in tumorigenesis, mutations are prevalent in CRC and are associated with poor prognosis. However, breakthroughs in drug development have led to the emergence of KRAS inhibitors as promising treatment options. This review discusses various classes of KRAS inhibitors, including covalent and non-covalent inhibitors, as well as combination therapies aimed at enhancing efficacy and overcoming resistance mechanisms. It highlights recent clinical trials evaluating the efficacy of KRAS inhibitors either as monotherapy or in combination with other agents, such as anti-EGFR antibodies. Despite challenges such as resistance mechanisms and tumor heterogeneity, the development of KRAS inhibitors represents a significant advance in CRC treatment and holds promise for improving patient outcomes in the future.